CHD is a historically strong compounder, but recent results show flat or negative growth, and management has cut guidance for 2025. Despite strong execution and brands, domestic sales have stalled, ...

I maintain a neutral view on Church & Dwight Co. due to concerns about slowing domestic growth, which could impact its valuation multiples. Despite solid 4.2% organic sales growth in 4Q24, CHD's ...

Cardio Diagnostics, Inc, a biotechnology company making cardiovascular disease prevention and early detection more accessible, personalized and precise, announces the launch of its patent-pending ...

Please provide your email address to receive an email when new articles are posted on . CDC data show an overall decline in the prevalence of self-reported CHD in the U.S. slowed during the past ...